This company has been marked as potentially delisted and may not be actively trading. Flex Pharma (FLKS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock FLKS vs. PYRGF, OSTX, ATNM, EGRX, ELYM, NBRV, AADI, NNVC, IBIO, and TAOXShould you be buying Flex Pharma stock or one of its competitors? The main competitors of Flex Pharma include PyroGenesis Canada (PYRGF), OS Therapies (OSTX), Actinium Pharmaceuticals (ATNM), Eagle Pharmaceuticals (EGRX), Eliem Therapeutics (ELYM), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), NanoViricides (NNVC), iBio (IBIO), and Synaptogenix (TAOX). Flex Pharma vs. Its Competitors PyroGenesis Canada OS Therapies Actinium Pharmaceuticals Eagle Pharmaceuticals Eliem Therapeutics Nabriva Therapeutics Aadi Bioscience NanoViricides iBio Synaptogenix Flex Pharma (NASDAQ:FLKS) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership. Which has higher earnings and valuation, FLKS or PYRGF? PyroGenesis Canada has higher revenue and earnings than Flex Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFlex Pharma$840K13.55-$21.92MN/AN/APyroGenesis Canada$9.14M5.80-$21.12M-$0.01-28.31 Do insiders & institutionals have more ownership in FLKS or PYRGF? 14.4% of Flex Pharma shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 7.6% of Flex Pharma shares are held by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is FLKS or PYRGF more profitable? PyroGenesis Canada has a net margin of -115.14% compared to Flex Pharma's net margin of -1,208.42%. PyroGenesis Canada's return on equity of 0.00% beat Flex Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Flex Pharma-1,208.42% -98.04% -83.37% PyroGenesis Canada -115.14%N/A -60.81% Does the media refer more to FLKS or PYRGF? In the previous week, PyroGenesis Canada had 3 more articles in the media than Flex Pharma. MarketBeat recorded 3 mentions for PyroGenesis Canada and 0 mentions for Flex Pharma. Flex Pharma's average media sentiment score of 0.00 equaled PyroGenesis Canada'saverage media sentiment score. Company Overall Sentiment Flex Pharma Neutral PyroGenesis Canada Neutral Which has more volatility & risk, FLKS or PYRGF? Flex Pharma has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. SummaryPyroGenesis Canada beats Flex Pharma on 7 of the 10 factors compared between the two stocks. Get Flex Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FLKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLKS vs. The Competition Export to ExcelMetricFlex PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.38M$763.52M$5.47B$9.53BDividend YieldN/A4.84%4.74%4.08%P/E RatioN/A1.3428.6723.80Price / Sales13.5525.20422.2688.08Price / CashN/A19.5635.4557.96Price / Book1.246.778.275.55Net Income-$21.92M-$4.28M$3.24B$259.03M Flex Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLKSFlex PharmaN/A$0.63+5.1%N/A-76.6%$11.38M$840K0.004Gap UpHigh Trading VolumePYRGFPyroGenesis Canada0.3773 of 5 stars$0.29+0.7%N/A-53.5%$54.23M$9.14M-4.8390News CoverageGap UpHigh Trading VolumeOSTXOS Therapies2.0837 of 5 stars$1.83+1.7%$18.00+883.6%N/A$51.42MN/A-2.13N/AATNMActinium Pharmaceuticals1.9532 of 5 stars$1.61-6.4%$4.00+148.4%-75.6%$50.23MN/A-1.1630News CoverageEGRXEagle Pharmaceuticals1.9577 of 5 stars$3.69flatN/A-33.3%$47.92M$257.55M0.00100Gap DownELYMEliem TherapeuticsN/A$1.60+10.3%N/A-80.9%$47.60MN/A-3.029NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi Bioscience0.4862 of 5 stars$1.81-7.2%$1.67-7.9%+15.1%$44.70M$25.07M-0.7940Upcoming EarningsNNVCNanoViricides0.6412 of 5 stars$1.70flatN/A-24.8%$27.32MN/A-2.3620IBIOiBio1.288 of 5 stars$0.69-2.8%$5.00+624.7%-68.0%$11.40M$375K0.00100News CoverageTAOXSynaptogenixN/A$6.86+5.2%N/AN/A$9.06MN/A-0.684 Related Companies and Tools Related Companies PyroGenesis Canada Competitors OS Therapies Competitors Actinium Pharmaceuticals Competitors Eagle Pharmaceuticals Competitors Eliem Therapeutics Competitors Nabriva Therapeutics Competitors Aadi Bioscience Competitors NanoViricides Competitors iBio Competitors Synaptogenix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLKS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flex Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Flex Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
